Treatment News : Protease Inhibitors During First Trimester Raise Risk of Premature Births

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 11, 2013

Protease Inhibitors During First Trimester Raise Risk of Premature Births

Pregnant women’s use of protease inhibitors (PIs) in the first trimester increases their risk of premature birth by over half, aidsmap reports; but triple nucleoside or non-nucleoside reverse transcriptase inhibitors (nukes/non-nukes) are not associated with these risks. Supporting findings from past research, the study was published in the online edition of The Journal of Infectious Diseases.

Researchers from the U.S. Pediatric HIV/AIDS Cohort Study (PHACS) examined expectant mothers’ use of antiretrovirals during pregnancy. They found that out of 1,869 births of a single child (as opposed to twins), 346 (19 percent) were preterm births (before the end of the 37th week of pregnancy), 55 percent of which were spontaneous, meaning they occurred after preterm labor or the rupture of the amniotic sac without other complications. The investigators found that treatment with protease inhibitors during the first trimester increased the likelihood of preterm delivery by 55 percent and spontaneous premature delivery by 59 percent.

The PIs associated with premature birth include Invirase (saquinavir), Norvir (ritonavir, which is often used to “boost” the medication levels of other antiretrovirals) and Kaletra (lopinavir/ritonavir). Nukes and non-nukes were not associated with preterm delivery, nor was antiretroviral (ARV) use in the second or third trimesters of pregnancy.

“HIV disease progression or effects of combination ARV on the immune system among women with indications for initiation of therapy before pregnancy may contribute to increasing preterm birth risk,” the researchers write in their study.

To read the aidsmap story, click here.

To read the study’s abstract, click here.

Search: HIV, protease inhibitors, first trimester, women, pregnant, premature birth, aidsmap, nucleoside, non-nucleoside reverse transcriptase inhibitors, nukes/non-nukes, U.S. Pediatric HIV/AIDS Cohort Study, PHACS, antiretrovirals, ARVs, Invirase, saquinavir, Norvir, ritonavir, Kaletra, lopinavir.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.